Storia in 13 fonti

Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Applied Digital (NAS

GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT, MTEN, NCRA, ZTG, EPSM, DBI, APLD. Losers include BYAH, NOTV.

Raccontata da

thehindubusinessline.com

economictimes.indiatimes.com

thisdaylive.com

cryptobriefing.com+1 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mese fa

Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Applied Digital (NAS

GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT, MTEN, NCRA, ZTG, EPSM, DBI, APLD. Losers include BYAH, NOTV.

originale

Timeline cronologica

martedì 9 giugno 2026·thehindubusinessline.com
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion
GSK is in negotiations to acquire cancer biotech Nuvalent for over $9 billion amid a surge in biotech mergers.
martedì 9 giugno 2026·cityam.com
GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal
GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.

Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Applied Digital (NAS

Confronto fonti

Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Applied Digital (NAS

Timeline cronologica

GSK in talks to buy cancer biotech Nuvalent for more than $9 billion

GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal

Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal

UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

GSK buys US biopharma company Nuvalent for $10.6B

Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK

GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal

GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B

UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Applied Digital (NAS

Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

GSK buys US biopharma company Nuvalent for $10.6B

GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent

Nuvalent vola a Wall Street: titolo in rialzo di quasi il 40% dopo l’annuncio dell’acquisizione da 10,6 miliardi di dollari da parte di Gsk…

$10. 6 billion deal: GSK to buy US cancer specialist Nuvalent

GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion

GSK acquires Nuvalent for $10.6 billion to rebuild its oncology business

Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK